ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments

Wang, Chenghao; Lu, Tong; Xu, Ran; Chang, Xiaoyan; Luo, Shan; Peng, Bo; Wang, Jun; Yao, Lingqi; Wang, Kaiyu; Shen, Zhiping; Zhao, Jiaying*; Zhang, Linyou*哈尔滨医科大学
Journal of Thoracic Disease2022-6DOI: 10.21037/jtd-22-494
2被引21阅读
引用收藏
分享

摘要

Background: There is increasing evidence of the effectiveness of immune checkpoint blockade (ICB) therapy for the treatment of lung adenocarcinoma (LUAD). However, the benefits of ICB therapy vary among LUAD patients. Due to the research dimension, existing biomarkers, such as programmed deathligand 1 (PD-L1) expression and tumor mutation burden (TMB), could not reflect the complex tumor environment, and had low prediction accuracy of ICB. Therefore, we aimed to uncover a prognostic biomarker that could also predict whether a patient would benefit from ICB therapy and other common treatments from multiple dimensions, so as to improve the prediction accuracy of pre-treatment patients. Methods: Based on the LUAD dataset retrieved from The Cancer Genome Atlas (TCGA), database, 50 immune-related hub genes were identified using weighted gene co-expression network analysis and univariate Cox regression analyses. An immune-related gene prognostic index (IRGPI) was constructed using a Cox proportional-hazards model based on 15 genes and validated using GSE72094 dataset. We tested its prognostic accuracy by Kaplan-Meier (K-M) survival curves of the two datasets and assessed its predictive power by comparing area under curve (AUC) of IRGPI with existing biomarkers. Subsequently, we analyzed the molecular and immune characteristics, and evaluated the benefits of ICB by PD-L1 expression and Tumor Immune Dysfunction and Exclusion (TIDE) analysis, predicted the inhibitory concentration 50 of common treatments drugs for two IRGPI score-related subgroups. Results: Patients in the IRGPI-high subgroup had lower overall survival (OS) than patients in the IRGPIlow subgroup in K-M survival curve in two cohorts. And IRGPI has AUC values of 0.715, 0.724, and 0.743 in 1, 2, and 3 years, respectively. A higher tumor mutation burden and PD-L1 expression and the tumor microenvironment (TME) landscape demonstrated that IRGPI-high subgroup patients may respond better to ICB therapy. Genomics of Drug Sensitivity in Cancer (GDSC) analysis indicated that the IRGPI-high subgroup showed greater sensitivity to chemotherapy. Conclusions: IRGPI is a prospective biomarker for evaluating whether a patient will benefit from ICB therapy and other treatments, and distinguishing patients with different molecular and immune characteristics.

学科与关键词

关键词
Immune-related genesimmune checkpoint blockade therapy (ICB therapy)lung adenocarcinoma (LUAD)prognosis biomarkerimmune cell infiltration
相关
加载中…
  • Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
    Yi, Ming; Li, Anping; Zhou, Linghui; Chu, Qian; Luo, Suxia*; Wu, Kongming*Cancer Immunol Immunother, 2021, 70(6): 1705-1719.
  • Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma
    Zhou, Xiang; Xu, Ran; Lu, Tong; Wang, Chenghao; Chang, Xiaoyan; Peng, Bo; Shen, Zhiping; Yao, Lingqi; Wang, Kaiyu; Xu, Chengyu; Shi, Jiaxin; Zhang, Ren; Zhao, Jiaying; Zhang, Linyou*Scientific Reports, 2023, 13(1).
  • LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response
    Huang, Jihong; Yuan, Lu; Huang, Wenqi; Liao, Liwei; Zhu, Xiaodi; Wang, Xiaoqing; Li, Jiaxin; Liang, Wenyu; Wu, Yuting; Liu, Xiaocheng; Yu, Dong; Zheng, Yunna; Guan, Jian*; Zhan, Yongzhong*; Liu, Laiyu*Frontiers in Immunology, 2022, 13: 1064874.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Thoracic Disease
发表日期
2022-06
卷期
第 14 卷, 第 6 期
页码
2131-+
DOI
10.21037/jtd-22-494
语言
ENGLISH
期刊等级
4区
成果收录
SCIE

作者

  • W

    Wang, Chenghao (第一作者)

    2 · harbin med univ

  • L

    Lu, Tong

    2 · harbin med univ

查看全部 12 位作者收起作者
  • X

    Xu, Ran

    2 · harbin med univ

  • C

    Chang, Xiaoyan

    2 · harbin med univ

  • L

    Luo, Shan

    2 · harbin med univ

  • P

    Peng, Bo

    2 · harbin med univ

  • W

    Wang, Jun

    2 · harbin med univ

  • Y

    Yao, Lingqi

    2 · harbin med univ

  • W

    Wang, Kaiyu

    2 · harbin med univ

  • S

    Shen, Zhiping

    2 · harbin med univ

  • Z

    Zhao, Jiaying (通讯)

    2 · harbin med univ

  • Z

    Zhang, Linyou (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417